Genzyme Sues Lupin Over Generic Renvela Plans
The Cambridge, Mass-based drugmaker filed suit Thursday in the U.S. District Court for the District of Maryland, accusing Lupin of infringing six patents, including four it asserted against Lupin in March over the drug Renagel.
Renagel and Renvela are nonabsorbed, calcium-free, metal-free phosphate binders that are used to control serum phosphorus in patients...
Already a subscriber? Click here to login